ProZ92: Natural Psoriasis Treatment

Research
 
An evaluation of the effects on ProZ92 on proliferation of skin cells in culture

By J. Gibson, Ph.D., FACMG

Molecular/cellular biologist

Psoriasis is a condition characterized by hyperplasia (escalated cell growth rate) of the epidermal keratinocytes of skin causing flaky scales which are a hallmark of this disease. Skin is composed of an underlying dermis comprised of fibroblast cells covered by an epidermal layer composed of keratinocyte cells.

It is not clear if fibroblasts play a role in facilitating the increased level of keratinocyte growth, therefore experiments were performed in our laboratory to study the effects of Z92 on the growth characteristics of both cell types. Z92 was added intact and void of acetic acid to pure populations of fibroblasts and keratinocytes.

Twenty-eight 28 data points for each treatment were collected and evaluated using statistical methods to compare cell growth rates.

Data indicate that intact Z92 and fraction 1 ( Z92 void acetic acid) both significantly inhibited the growth of kertinocytes, but nether had any effect on fibroblasts. These preliminary laboratory studies and histological evaluation of skin treated with Z92 in a mouse model of psoriasis indicate that the compound inhibits the growth of keratinocytes and that this activity is specific for this cell type.

ProZ92 evaluation in a Murine model of psoriasis

By Dr. F. Kennedy

Psoriasis is an oftentimes devastating chronic recurrent papulosquamous dermatitis without an effective cure. Z92 has been developed for the treatment of psoriasis.

In a preliminary controlled study, Z92 has been applied topically on flaky skin (fsn/fsn) mice, which are an experimental model for psoriasis.

Z92 induced dramatic gross and microscopic changes similar to those of a chemical burn only on the hyperproliferative skin of flaky mice with minimal to no effects on control mice also treated once a week for up to seven weeks.

The treated necrotic skin remains attached firmly as a biological bandage for up to six weeks on flaky mice allowing healing of the underlying skin.

The reasons that this product specifically affects only affected skin so dramatically have not yet been fully determined but alteration in the keratinocytes and barrier function of the epidermis and its basement membrane are suspected to be responsible. This product may normalize the regulation of keratinocyte proliferation in psoriatic lesions as well.

This hypothesis is supported by in vitro tritiated thymidine uptake study finding that Z92 significantly reduced growth and division of epidermal keratinocytes but not dermal fibroblasts from normal and keloid tissues.

Clinical study results

Previous experience treating humans in with ProZ92 has been obtained in approximately 200 patients in Israel. All had previous treatments of various natures.

The results from these treatments consisted of symptomatic relief from itching, flaking and irritation.

None of the patients were receiving any oral or topical medications at the time of the ProZ92 treatments.

Treatment with ProZ92 continued until the lesions and symptoms disappeared.

The treatment periods ranged from two to 18 weeks.

Follow-ups after treatment ranged from seven months to three years and showed resolution of the psoriasis with no visible recurrences.

Here is a summary of the clinical trail conducted in compliance
with the protocol, cGCP, applicable regulatory requirements:

  • The extensive report includes over 300 pages and is 18 megabytes in size.
  • It was delivered to us in July, 2005 dated June, 2005.
  • The trials were a success.
  • The study concludes that 68 percent of patients experienced an improvement of 1 or more on the Physician’s Global Assessment (PGA).
  • 43 percent of users saw a Physician’s Global Assessment (PGA) reduction of 2 or more.
  • 17 percent saw a reduction of 3 or more.
  • 67 percent of patents who started with a PGA of 4 (the most severe in the patient population) experienced an improvement of 2 or more.
  • 89 percent of patients who started with a PGA of 4 (the most severe) experienced an improvement of 1 or more on a scale of 5 in the PGA.
  • 91 percent of the patents started the study with a condition classified as “deteriorating.”
  • 100 percent of the patients tested experienced no side effects while using ProZ92.
  • Based on this, data it is believed that if the medication protocol treatment period was longer, the results would have been even better.

The clinical trials on ProZ92 were conducted under the following:

  • FDA authorization #58983
  • Canadian Natural health product authorization #101392
 More information

> More before and after photographs
> ProZ92 usage instructions
 Scientific details
> Patent information
> ProZ92 toxicity information
 Guaranteed to work
ProZ92 is guaranteed to get you results or we'll refund your purchase price.
Click here for details.
 Buy now

Buy our psoriasis treatment online

> All purchases are covered by a 60-day, money-back guarantee
> Buy securely online


The Z92 Story | Testimonials | Photos | Research | Buy Now
Terms & Conditions | Privacy Policy | Guarantee | FAQs | Site Map


Tell a friend about ProZ92

Copyright © 2007 ProZ92 Ltd. All rights reserved. ProZ92 and the ProZ92 logo are trademarks of ProZ92 Ltd.

ProZ92 is an all-natural product that reduces the effects of the common skin condition known as psoriasis. Using a patented
formula, the product is an effective psoriasis treatment. ProZ92 works to counteract psoriasis skin itching and pain,
as well as the red, scaly patches on the skin caused by plaque, pustular, guttate and flexural psoriasis on all levels of the
Psoriasis Area Severity Index. ProZ92 is a great alternative to steroid and other treatments recommended by dermatologists.